Table 1.
Patient’s characteristics
| Patients | Gender | Mutation | CNS Manifestations | Age Epilepsy Onset | Duration of epilepsy prior to Everolimus | Antiepileptic drug therapy at baseline | VNS | KD | Prior Epilepsy Surgery | Prior SEGA Surgery | Age Everolimus Start |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | m | TSC1 | SEGA, SEN, RML | 4 years | 2 years | TPM | 6 years | ||||
| 2 | m | TSC2 | SEGA, SEN, RML | 3 months | 16 years 9 months | OXC | 17 years 3 mths | ||||
| 3 | f | TSC2 | SEGA, SEN, RML | 9 months | 12 years 3 months | VPA, LEV, PHT | 12 years 10 mths | ||||
| 4 | f | TSC2 | SEGA, SEN | 6 months | 5 years 6 months | LEV | y | 6 years 2 mths | |||
| 5 | f | TSC2 | SEGA, SEN | 7 months | 16 years 6 months | LEV, PGB | y | 17 years 1 mths | |||
| 6 | m | TSC2 | SEGA, SEN | 3 months | 6 years 9 months | RUF, ZNS | y | 6 years 11 mths | |||
| 7 | f | TSC1 | SEGA, SEN | 2 years 9 months | 16 years 3 months | OXC | 18 years 6 mths | ||||
| 8 | m | TSC2 | SEGA, SEN | 3 months | 1 year 9 months | TPM, LEV, VGB | 2 years 1 mths | ||||
| 9 | m | TSC2 | SEGA, SEN | 2 years | 4 years | VGB | 6 years 8 mths | ||||
| 10 | m | TSC1 | SEGA, SEN, RML | 4 months | 14 years 9 months | OXC, PGB | y | 15 years 6 mths | |||
| 11 | f | TSC1 | SEGA, SEN, RML | 2 years | 2 years | OXC, VGB | y | 3 years 11 mths | |||
| 12 | m | TSC2 | SEGA, SEN | 1 year 3 months | 5 years | RUF | y | 8 years 1 mths | |||
| 13 | m | TSC2 | SEGA, SEN, RML | 4 months | 5 years 9 months | VPA | 6 years 8 mths | ||||
| 14 | m | TSC2 | SEGA, SEN | 4 months | 0 year 9 months | VGB, LEV | y | 1 year | |||
| 15 | f | negative | SEGA, SEN | 1 year 3 months | 2 years | RUF, TPM | 3 years 3 mths |